Factors Influencing Older People's Disaster Preparedness Capacity: A Systematic Review.

Int J Older People NursSep 1, 2026
Clinical ResearchGeriatricsPreventive Medicine / Public HealthOpen access

Seo-Jin Lee, Yujin Hur

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined factors influencing disaster preparedness capacity among older adults, analyzing 11 quantitative studies. Key findings indicate that individual, social, and environmental factors significantly impact preparedness. Notably, demographic characteristics, health status, and community involvement were highlighted as critical elements affecting readiness for disasters.

Key findings

  • Individual factors like age, education, and health status influence disaster preparedness.
  • Social factors such as family discussions and community involvement are crucial.
  • Environmental factors, including housing safety and access to information, affect preparedness.

Why it matters

Understanding the multifaceted influences on disaster preparedness in older adults is essential for developing effective interventions. Clinicians can enhance preparedness by addressing individual needs and fostering social and environmental support.

Source

PubMed · PMID 42632095Free full text on PubMed Central

Published in Int J Older People Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.